Compare CBNK & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBNK | CAPR |
|---|---|---|
| Founded | 1974 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.3M | 584.9M |
| IPO Year | 2018 | 2011 |
| Metric | CBNK | CAPR |
|---|---|---|
| Price | $41.23 | $8.99 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $44.08 | $27.25 |
| AVG Volume (30 Days) | 116.3K | ★ 3.8M |
| Earning Date | 10-26-2026 | 11-10-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | ★ 60.85 | N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.98 | N/A |
| Revenue Next Year | $10.68 | $85.77 |
| P/E Ratio | $17.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.40 | $2.96 |
| 52 Week High | $44.76 | $40.37 |
| Indicator | CBNK | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 49.05 | 52.58 |
| Support Level | $35.70 | $7.78 |
| Resistance Level | $44.76 | $10.62 |
| Average True Range (ATR) | 0.81 | 1.05 |
| MACD | -0.31 | 0.07 |
| Stochastic Oscillator | 3.19 | 51.87 |
Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage. The company generates majority revenue from the Commercial bank sector. Commercial Banking division focuses on providing personalized service to commercial clients throughout the operations supplemented by lending outside primary market as well as engaging in government guaranteed lending on a national basis.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.